May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Assessing Behavior and Readiness for Behavior Change in Patients Taking Ocular Hypotensive Therapy
Author Affiliations & Notes
  • G. F. Schwartz
    Glaucoma Consultants, Baltimore, Maryland
  • K. Plake
    Purdue University School of Pharmacy and Pharmaceutical Sciences, West Lafayette, Indiana
  • M. A. Mychaskiw
    Pfizer Inc, New York, New York
  • Footnotes
    Commercial Relationships G.F. Schwartz, Santen, F; Allergan, F; Pfizer Inc, F; Pfizer Inc, C; Merck, R; Pfizer Inc, R; K. Plake, None; M.A. Mychaskiw, Pfizer Inc, E.
  • Footnotes
    Support Research supported by Pfizer Inc.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 2401. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. F. Schwartz, K. Plake, M. A. Mychaskiw; Assessing Behavior and Readiness for Behavior Change in Patients Taking Ocular Hypotensive Therapy. Invest. Ophthalmol. Vis. Sci. 2007;48(13):2401.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: Nonadherence and poor persistence with ocular hypotensive (OH) medications are common. An instrument was developed to identify patients whose behavior may need to be improved and who may be ready to change.

Methods:: The content and face validities of the 62-item survey, which was based on the Transtheoretical Model of Change, were confirmed by 9 glaucoma specialists. The self-administered survey includes patient demographics, patient evaluations of health and medications, use of and difficulties taking OH medications, and visual function. The questionnaire was administered anonymously in a glaucoma referral practice to consecutive patients prescribed ≥1 OH medication with no history of trabeculectomy.

Results:: In all, 102 patients were surveyed of whom 63.6% were ≥60 year old, 84.3% had glaucoma, 63.7% were diagnosed >3 years before, 45.1% were taking 1 OH medication, and 16.7% were taking >2 medications. The vast majority (86.6%) reported administering eyedrops every day, 12.4% were taking action to meet this goal, and 1% were contemplating such action; 78.6% reported administering eyedrops at the same time every day and the remainder were taking or preparing/contemplating such action (17.3% and 4.0%, respectively). Adherence score (23.98±1.29, possible/actual range 0-25/20-25) and number of adherence problems (0.92±1.08, range 0-5) were negatively correlated (r=-0.611, P<0.0001), while number of adherence problems and number of side effects were positively correlated (0.84±1.26, range 0-6; r=0.349, P<0.0001).

Conclusions:: Identifying patients’ behaviors and barriers to medication adherence and persistence will allow appropriate interventions to be designed.

Keywords: clinical (human) or epidemiologic studies: health care delivery/economics/manpower • clinical (human) or epidemiologic studies: outcomes/complications • clinical (human) or epidemiologic studies: risk factor assessment 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.